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esponsibility of InstAbstract Epigenetic modiﬁcations alter chromatin structures and consequently affect transcription and
cellular functions. Major epigenetic markers include DNA methylation and histone acetylation and
methylation. The modiﬁcations are reversible and are achieved in aid of relative enzymes. Much effort has
been directed at the understanding of the chemical mechanisms of individual catalytic reactions, which
can serve as a foundation for inhibitor development. Among the many methods deployed, structural
studies have proven the most effective for understanding enzyme-mediated modiﬁcations and have
provided support for the development of lead-candidate drug inhibitors. This review brieﬂy summarizes
the existing knowledge on the catalytic mechanisms of the major epigenetic modiﬁcation enzymes, with
an emphasis on the structural information and inhibitors of these enzymes.
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Duo Lu1421. Introduction
Transcriptional regulation governs gene expression, and conse-
quently deﬁnes the fate of individual cells. Early studies in the
ﬁeld of transcriptional regulation have been focussed on the
identiﬁcation of key factors that inﬂuence the expression of certain
genes, which led to the discovery of transcription factors and their
correlate DNA elements, such as promoters and enhancers. The
attempt to explain the mechanism of these regulators has revealed
the importance of the accessibility of DNA promoter regions for
RNA polymerase. For a simple linear model, transcription factors
bind their DNA elements and recruit RNA polymerase to the gene
for the transcription initiation, or in the case of repression, exclude
the polymerase from the gene.
A gene is, however, never in a straight line. In eukaryotic cells,
genomic DNA is packed into the nucleus in the form of
chromosome. The nucleosome is the packing unit for the
chromosome, which comprises of 147 bp of DNA in 1.7 left-
handed superhelical turns wrapping around a histone octamer
(Fig. 1). Two sets of the four core histones, H2A, H2B, H3 and
H4, build up the octamer, and the linker histone H1/H5 binds an
additional 20 bp DNA at the start and end of the nucleosome. An
array of nucleosomes is further folded into a 30 nm ﬁbre and
possibly other high-order structures.
The high-order structure is regulated by the modiﬁcations on
the histones and DNA, which are generated by various modiﬁca-
tion enzymes. The most common modiﬁcations are histone
acetylation/deacetylation, histone methylation/demethylation, and
DNA methylation/demethylation. These modiﬁcations are believed
to be inheritable, and therefore called epigenetic markers. Altera-
tions in the epigenetic markers have been associated with many
diseases. For example, hypomethylation of CpG sites has been
related to tumour genesis1. Small molecule inhibitors have been
developed against the modiﬁcation enzymes, in an attempt to
affect the structure of the chromosome and consequently regulate
transcription and cell function.
A full understanding of the chemical mechanisms of individual
enzymes is essential to inhibitor development, and structural
studies have been shown to be an efﬁcient means to explore
enzyme mechanisms and inhibitor design. After a few decadesFigure 1 Nucleosome structure. Ribbon diagram of nucleosome core
structure. The DNA double helix is in grey, and 4 core histones are
coloured differently: H2A in purple, H2B in light purple, H3 in green,
and H4 in blue.efforts, our knowledge of epigenetic modiﬁcation has been greatly
enriched. This review attempts to brieﬂy summarize the mechan-
isms of the most common modiﬁcation enzymes and the enzyme
inhibitors.2. Histone acetylation
N-terminal tails of core histones are subject to reversible post-
translational acetyl modiﬁcation. Taking acetyl-coenzyme A
(AcCoA) as a cofactor, histone acetyltransferases (HATs) attach
an acetyl group to the ε-amino group of substrate lysine residues.
HATs have been grouped into 5 major families: HAT1, Gcn5/
PCAF, MYST, p300/CBP, and Rtt109, and some additional
proteins also display HAT activity.
HATs in the 5 major families share the structural feature of a 3-
stranded anti-parallel β-sheet with an α-helix spanning the length
of sheet at one side. This structural motif contributes to the binding
of cofactor AcCoA, and its ﬂanking regions contribute to substrate
speciﬁcity, which vary greatly between the different HAT families
(Fig. 2a).
The catalytic mechanism of Gnc5/PCAF and MYST HATs has
been extensively studied. It involves the deprotonation of substrate
lysine ε-amino group, which is achieved through a water
molecule-mediated contact to a structurally conserved glutamate
residue (Fig. 2b and c). Subsequently, the lysine residue makes a
nucleophilic attack on the acetyl moiety of AcCoA, through a
putative tetrahedral intermediate, resulted in an acetylated lysine2.
Alternatively, a ping-pong mechanism has been proposed for
MYST HATs, which included an additional middle step of MYST
auto-acetylation on a conserved cysteine residue (Fig. 2c), before
the acetyl group was transferred to the substrate lysine3.
A hit-and-run (Theorell–Chance) mechanism has been proposed
for p300/CBP HATs, based on the crystal structure of p300 HAT
complexed with a bi-substrate inhibitor, Lys–CoA4. The highly
dynamic mechanism was proposed based on the fact that a more
authentic bi-substrate analogue inhibited p300 activity much less
effectively than Lys–CoA, which argued against a standard
sequential mechanism. No general base was identiﬁed for depro-
tonation of the substrate ε-amino group (Fig. 2c). Only a hydrogen
bond was found between the ε-amino group and the main-chain
carbonyl group of a tryptophan residue in p300. A tyrosine residue
was thought to stabilize the leaving group, CoA.
The mechanisms for HAT1 and Rtt109 classes HATs are not
clear. A crystal structure is available for the ternary complex of
HAT1, cofactor AcCoA, and a histone H4 peptide containing
residue K125. Superimposing HAT1 with the Gcn5 active site has
shown a glutamate residue located at the similar position of the
one in Gcn5, which has been proven functionally important
(Fig. 2c). Mutation at this residue greatly impairs the catalytic
ability of HAT1. However, the ordered water molecule in Gcn5
has not been detected in HAT1 structures.
Rtt109 by itself has a very weak catalytic ability to acetylate
histone. The activity is, however, elevated upon association with
its chaperones such as yeast Vps75 and Asf1. The structure of
Rtt109 complexed with Vps75 reveals little conformational
difference from its isolated form (Fig. 2c), which implies that
the enhanced activity is possibly due to an increase in substrate
binding6. Yet mutations at the Rtt109–Vps75 interface do not
affect Asf1–Rtt109 activity, suggesting a different mechanism for
Asf1 stimulation on Rtt109.
Figure 2 Mechanism of histone acetylation. (a) Ribbon diagrams of the 5 major HAT classes. The common structural feature is coloured in gold.
Substrates are coloured in purple, and cofactors are coloured in grey. (b) Catalytic mechanism of Gcn5 HATs. (c) The left panel shows the ribbon
diagram of Gcn5 catalytic domain in grey. Key residues are shown in stick model, CoA in product complex is shown in lime, and substrate is in
gold. Cofactor AcCoA in green is modelled in to indicate the position of acetyl group, which clashes with the substrate lysine residue. Presumably
the true spatial location of the lysine would be closer to the water molecule, before the reaction takes place, which would be more favourite to the
lysine residue activation. The central panel shows the stick models of catalytic cores of HAT1, MYST, and p300. Note the position similarity
between gluatamate residues in HAT1, Gcn5 and MYST. The cysteine in MYST is auto-acetylated. The inhibitor Lys–CoA is bound in p300,
which mimics both AcCoA and lysine substrate. The right panel shows the complex of Rtt109 and Vps75. Rtt109 is in green, Vps75 is in purple,
and the cofactor AcCoA is in grey.
Epigenetic modiﬁcation enzymes: catalytic mechanisms and inhibitors 143Bi-substrate inhibitors have been the most prominent candidates
for HATs inhibition7, and crystal structures of HAT-inhibitor
complexes demonstrated that the inhibitor binding site overlapped
with the cofactor and substrate binding sites (Fig. 2c). Some
natural products showed an ability to inhibit HATs8–12, such as
anacardic acid, garcinol, curcumin, epigallocatechin-3-gallate
(EGCG), and plumbagin. High-throughput screening identiﬁed a
family of isothrazolones, while virtual screens produced
pyrozolone-containing small molecules as inhibitors13. A recent
study demonstrated that a series of 6-alkylsalicylates could inhibit
MYST HATs14.3. Histone deacetylation
Histone deacetylases (HDACs) reverse the acetylation modiﬁca-
tion. They are classiﬁed into 5 groups, classes I, IIa, IIb, III and
IV, according to their phylogenetic distance15. Mechanically theycan be divided into two large groups. Class I, IIa, IIb, and IV
HDACs deploy a zinc ion in their catalytic mechanism, while class
III Sir2-like HDACs deliver their catalytic ability in a
nicotinamide-adenine-dinucleotide (NAD+)-dependent manner.
The catalytic domains of zinc-ion dependent HDACs share a
common Rossmann fold structure16,17, which includes a central
8-stranded parallel β-sheet with several helices at both sides.
The zinc ion, chelated by a histidine and two aspartate residues is
located at the C-terminal side of the β-sheet. The scissile acetyl
group binds to the zinc ion causing electronic polarization.
A histidine–aspartate charge relay system has been proposed to
perform as the general base to deprotonate the attacking water
molecule. Another pair of histidine–aspartate amino acid residues
and in certain cases, histidine–asparagine pair is believed to
stabilize the deacetylated product residue (Fig. 3a and c).
Class III Sir2-like HDACs consist of 2 globular domains
(Fig. 3c)18. The large domain has a Rossman fold with a
6-stranded parallel β-sheet and 6 α-helices. The small domain is
Figure 3 Mechanism of histone deacetylation. (a) Catalytic mechanism of zinc ion-dependent HDACs. (b) Catalytic mechanism of NAD+-
dependent HDACs. (c) Structures of HDACs. The ribbon diagram of a zinc-dependent HDAC (PDB: 1ZZ0) is in green. Key residues at catalytic
core are in grey, and an acetate ion in gold is bound at the core. The stick model next to the green ribbon model shows inhibitor SAHA bound at
the catalytic core (PDB: 1T69). SAHA is in blue, and core residues are labelled. The ribbon diagram of a NAD-dependent HDAC (Sir2) is in grey
(PDB:1S7G). Key residues at Sir2 catalytic core are shown in stick models, and the cofactor NAD+ is in green stick model. The substrate in gold is
a model generated from a structure of Sir2 complex bound with a p53 peptide in absent of NAD+ (PDB: 1YC5).
Duo Lu144composed of a 3-stranded anti-parallel β-sheet and 2 α-helices. A
zinc binding motif is present in the small domain remote from the
active site, and can greatly affect the catalytic ability of the HDAC.
Loss of the zinc ion abolishes deacetylase activity. The cofactor
NAD+ binding site is located between the two domains and C-
terminal to the β-sheet of the large domain.
The mechanism of the class III HDACs has not been clearly
resolved. The proposed mechanism (Fig. 3b and c)19,20 involves an
initial cleavage step of the nicotinamide group from NAD+, which
is in response to the substrate acetyl-lysine attack on the C1′ of
NAD+. A conserved histidine residue performs as the general base
to deprotonate 2′–OH group of ADP-ribose, which makes an
intermolecular attack on the O-alkylamidate to create a 1′,2′-
bicyclic intermediate species. A water molecule subsequently
hydrolyzes the intermediate species to yield deacetylated lysine
and 2′-O-acetyl ADP ribose.
Two HDAC inhibitors have the approval from the US Food
and Drug Administration (FDA): vorinostat (suberoylanilide
hydroxamic acid, SAHA) for treatment of refractory cutaneous
T-cell lymphoma (CTCL)21, and depsipeptide (romidepsin) for
treatments of CTCL and peripheral T-cell lymphoma (PTCL)22.
SAHA belongs to the hydroxamic acid inhibitor group23, whichhas several other compounds that are under clinical trials, such as
givinostat, abexinostat, belinostat, resminostat, and quisinostat. In
addition, benzamide compounds entinostat and mocetinostat, and
fatty acids valproic acid and butyrate are also in clinical trials24,25.
All these inhibitors target zinc ion-dependent HDACs, and
existing crystal structures show the binding site at the zinc ion
region (Fig. 3c).
Nicotinamide is a by-product of class III HDAC-mediated
deacetylation, and displays a noncompetitive inhibitory ability
with these enzymes26. Another compound found to inhibit class III
HDACs is suramin, which competes for the binding-sites of both
NAD+ and acetyl-lysine substrate, as displayed in the crystal
structure of a suramin molecule complexed with two SIRT5
molecules27.4. Histone methylation
Both lysine and arginine residues are subject to methylation
modiﬁcation. Histone lysine methyltransferases (HKMTs) are
classiﬁed mostly based on their substrate protein domain or
sequence homology next to the target lysine28. Eight classes have
Epigenetic modiﬁcation enzymes: catalytic mechanisms and inhibitors 145been designated for HKMTs: HKMT1–8. HKMT1s methylate
H3K9. HKMT2 family enzymes target H3K4. HKMT3 methylates
H3K36 and H4K20. HKMT4 comprises the only non-SET-domain
protein DOT1L, and is responsible for the methylation of H3K79.
HKMT5 family is speciﬁed in mono-methylation of H4K20, while
others can further methylate H4K20me to H4K20me2/3. HKMT6
performs as a subunit of polycomb repressive complex 2 (PRC2)
and methylates H3K27. HKMT7 contains Set7/9 protein only,
which mono-methylates H3K4 and some non-histone proteins,Figure 4 Mechanisms of histone methylation and demethylation. (a) Ribb
are in grey, and substrates are in gold. A regulatory protein CoREST in p
domain histone methyltransferases. The right panel shows the catalytic core
stick model, and the modiﬁed lysine (meK) is in gold. (c) The catalytic m
mechanism of JmjC domain histone lysine demethylases. (e) The catalytic c
are in a green stick model, and the substrate or substrate analogue molecusuch as p53, DNA methyltransferase 1 (Dnmt1) and nuclear factor
kappa B (NFκB). RIZ1 is the only member of HKMT8, and is
responsible for H3K9 methylation.
Histone arginine methyltransferases (HRMTs) are classiﬁed into
4 groups: HRMT I–IV, based on the modiﬁcation they are able to
accomplish. Type I HRMTs make asymmetrical modiﬁcation on
the target arginine by di-methylating only one guanidine nitrogen.
Type II HRMTs perform symmetrical modiﬁcation by transferring
one methyl group to each of the guanidine nitrogen atoms. Typeon diagrams of histone lysine methylases and demethylases. Cofactors
urple is shown bound to LSD1. (b) The catalytic mechanism of SET
in a product complex. Key residues are in grey, cofactor is in a green
echanism of LSD1-like histone lysine demethylases. (d) The catalytic
ores of histone lysine demethylases. Key residues are in grey, cofactors
le is in gold.
Duo Lu146III HRMTs have similar activity as Type II, but have additional
ability to mono-methylate the internal nitrogen atom ω–N of
arginine residues in a peptide. Type IV HRMTs only modify ω–N
with mono-methylation.
Most histone methyltransferases have a SET domain for their
function to methylate substrate of amino acid residues, either
lysine or arginine. A series of β-strands fold into 3 discrete sheets
that surround a knot-like structure to form a SET domain
(Fig. 4a)29. SET domains perform at a high pH, about 1030. The
target lysine is therefore considered deprotonated at this pH, and
its ε-amino group can perform naturally as a nucleophile to attack
cofactor S-adenosyl-L-methionine (SAM). The methyl group of
SAM goes through a triangular bi-pyramid intermediate state, and
eventually covalently binds to ε-amino group of lysine or
guanidine group of arginine, which consequently converts SAM
into S-adenosyl-L-homocysteine (SAH) (Fig. 4b).
SAM binds to the non-SET-domain lysine methyltransferase,
DOT1L31 in an extended conformation, different from its ‘U-
shaped’ conformation found in SET binding (Fig. 4a). The SAM-
binding pocket in DOT1L is negatively charged, and a channel
made of conserved residues is thought to serve as a substrate lysine
binding, which leads to the buried cofactor SAM31. No structure is
available for substrate-bound DOT1L, and it is not completely
clear how the lysine amino group is deprotonated. The DOT1L
target H3K79 lysine is present in the histone globular core region
rather than in the histone tails. The methylation at H3K79 opens the
conformation of the chromatin region, which makes it signiﬁcant in
epigenetic studies.
Many inhibitors have been developed against SET domains.
Initial inhibitors included SAH and sinefungin32, which are
analogues to SAM. They showed poor selectivity among histone
methyltransferases. Later studies found a HKMT G9a inhibitor,
BIX-01294. The compound occupied the substrate-binding groove
of a G9a-like methyltransferase, according to the crystal structure
of their complex33. Based on this structural information, BIX-
01294 was modiﬁed into a new potent inhibitor, UNC022434,
which displayed 7-fold higher potency, and 1000-fold higher
selectivity in biochemical assays. However, UNC0224 showed
lower potency than BIX-01294 in cellular assays, which is
possibly due to its poor cell membrane permeability and low
lipophilicity. A further modiﬁcation generated UNC063835, which
showed more potent inhibition and less toxicity in cellular assays.
The ﬁrst DOT1L inhibitor was EPZ00477736, a SAM analogue,
which replaced the methionine amino acid moiety with a urea and
introduced a basic amine mimetic of the positively charged
sulfonium group. The compound was promising in both biochem-
ical and cellular assays, but displayed a poor pharmacokinetics
property due to a highly polar surface, which impaired passive
membrane permeability. Based on a detailed analysis of the crystal
structural features of the DOT1L-SAM complex31, new SAM
analogues were designed to further modify the 6-amino group. The
latest compounds displayed IC50 values around 110 nM, with high
selectivity towards DOT1L37.
The ﬁrst HRMT inhibitors were AMI1–938. AMI-1 was found to
occupy the arginine-binding pocket and showed a high degree of
HRMT speciﬁcity. The AMI compounds were further investigated
with modiﬁcations39 and mix-combinations40. A new inhibitor, a
pyrozole-amide derivative, was found in a high-throughput
approach41. Further investigation found that these compounds did
not perform in cellular assays, which was possibly due to poor cell
permeability42. Alantodapson was another leading compound pro-
duced from a combination approach of virtual and biological assaysusing RmtA enzyme, which displayed a good permeability43.
Further improvements have been made on its activity44 and
stability45.5. Histone demethylation
There are two classes of histone lysine demethylases: lysine
demethylase-like family and Jumonji C-terminal domain family.
Lysine demethylase 1 (KDM1 or LSD1) removes mono- or di-
methylation with the help of the co-factor ﬂavin adenine dinucleo-
tide (FAD). The catalytic core of KDM1 has an N-terminal
SWIRM domain and a C-terminal amine oxidase domain
(AOD). The 2 domains pack against each other to form a globular
structure (Fig. 4a). The AOD comprises of 2 lobes, the substrate-
binding lobe and the FAD-binding lobe, leaving the active site at
the interface of the two lobes.
The proposed mechanism of KDM1 involves the cofactor FAD
oxidizing the substrate amine to an imine through a hydride
transfer mechanism46. The reaction was subsequently completed
with the hydration of the imine to produce an N,O-hemiacetal,
which collapsed to formaldehyde and amine (Fig. 4c and e1).
FADH2 or FADH
−, the reduced form of FAD, was re-oxidized by
molecular oxygen, which led to the production of H2O2
47,48.
The Jumonji C-terminal domain (JmjC) family of histone demethy-
lases have the ability to remove all types of methylation with the help
of cofactors Fe2+ and α-ketoglutarate. The JmjC domain has a double
stranded β-helical fold, so-called ‘jelly roll’ structure, which forms the
catalytic pocket (Fig. 4a). Additionally there is a zinc ion-binding
motif, which is essential for the enzymatic activity.
The Fe2+ ion is coordinated with 3 conserved amino acid residues,
including 2 histidines and a glutamate from one side of the catalytic
pocket wall. The cofactor α-ketoglutarate is bound to Fe2+ in a
bidentate manner, and is further stabilized with 3 amino acid residues
from the other side of the catalytic pocket. The demethylation
mechanism involves several steps. First the Fe2+ is oxidized to Fe3+
by molecular oxygen. This produces a superoxide radical species,
which attacks the cofactor α-ketoglutarate and leads to the release of a
CO2 and the generation of a Fe
4+-oxo intermediate. The intermediate
oxidizes the substrate methyl group and generates a carbinolamine that
spontaneously releases formaldehyde to complete the demethylation on
the substrate lysine (Fig. 4d and e2)49.
Histone arginine demethylation remains as a speculation,
based on the existence of citrulline in histones50. However, no
biochemical pathway has been identiﬁed to carry out arginine
demethylation.
LSD1 has been a major target studied so far for the development
of inhibitors against HKDMs. Three classes of compounds have
been examined: polyamine analogues51, monoamine oxidase inhi-
bitor PCPA (trans-2-phenylcyclopyropylamine) variants52,53, and
H3 peptides54. Inhibitors against JMJD2 demethylase are mainly
cofactor 2-OG analogues or bi-substrate inhibitors55,56. A few
crystal structures exist for JMJD2 in complexes with inhibitors57.
A recent high-throughput assay reported numerous inhibitors against
LSD1 and JMJD2c, which required further validation58.6. DNA methylation and demethylation
DNA methyltransferases modify DNA bases with a methyl group.
The most common methylation is cytosine 5′-methylation. Three
DNA methyltransferases are found in mammals: Dnmt1, Dnmt3a
Figure 5 Mechanism of DNA methyltransferases. (a) Schematic diagram of the catalytic mechanism. (b) Catalytic core with an intermediate
substrate and cofactor bound. The cofactor is in green, the substrate is in gold, and key residues in Dnmt1 are in grey. (c) Ribbon diagram of
Dnmt1 bound to an intermediate DNA substrate. (PDB: 4DA4).
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dependent MTase fold’, which is comprised of a 7-stranded β-
sheet and 3 helices at each side of the β-sheet. The cofactor SAM
binds in the pocket formed by the core structure. The nucleotide to
be methylated ﬂips out of the DNA double helix and points into
the pocket towards the cofactor SAM (Fig. 5b and c). The
mechanism involves a conserved cysteine residue in the catalytic
loop of Dnmt making nucleophilic attack on the C6 of the cytosine
ring, which ends with a covalent bond between the enzyme and
DNA. Consequently, the C5 of the cytosine is strongly activated,
and attacks the methyl group of the cofactor SAM. The reaction
produces a methylated C5 with a proton attached. Through an
unknown process, the proton at C5 is removed, and the enzyme–
DNA covalent bond is resolved (Fig. 5a).
Two Dnmt inhibitors have approval from FDA: azacitidine for
the treatment of Myeloid Dysplasic Syndrome (MDS), and decita-
bine for the treatment of Acute Myeloid Leukaemia (AML). Both of
them are cytosine analogues which incorporate into DNA to block
methylation but lead to great cytotoxicity. To lower toxicity, some
non-nucleoside inhibitors have been developed, such as hydralazine
and procainamide, which have been assessed for their potential to
induce hypomethylation in solid tumours. However, these com-
pounds showed limited activity in living cells59.
There are two mechanisms of DNA demethylation: passive and
active demethylation. The passive demethylation pathway is depen-
dent upon DNA replication, which generates a new unmethylated
strand of DNA. The hyper-methylation state is maintained through
the inhibition of DNA methyltransferases. The active demethylation
pathway has long been elusive, until a recent suggestion was made
for the involvement of cytosine hydroxymethylation, which is
followed with the Base Excision Repair (BER) pathway, to achieve
the demethylation on DNA60. In addition, hydroxymethylation by
itself has been considered an epigenetic marker61.
Ten Eleven Translocation (TET) enzymes hydroxylate 5-
methylcytosine to 5-hydroxymethylcytosine. The catalytic domain
of TET enzymes is composed of a cysteine-rich region and adouble-stranded β-helix region62, and belongs to the dioxygenase
superfamily, the same as JmjC histone demethylases. The enzymes
utilize α-ketoglutarate and Fe2+ ion to oxidize 5-methylcytosine into
5-hydroxylmethylcytosine, in a mechanism similar to JmjC. The
cofactor analogue inhibitors for JmjC enzymes are likely to function
against TET enzymes. Indeed, oncometabolite 2-hydroxyglutarate
has been found to be a competitor of cofactor α-ketoglutarate (α-
KG)63 and inhibit both histone demethylases and TET hydroxylases.7. Concluding remarks
Epigenetic modiﬁcations affect a wide spectrum of cellular
functions and represent a fundamental question to address in life
science. Genome-wide identiﬁcation of the epigenetic markers has
been undertaken for a better understanding of the network of
transcriptional regulation, and histone acetylation, methylation and
DNA methylation are the major markers in this analysis. Epige-
netic modiﬁcations are mostly reversible, and are achieved by
families of related enzymes, namely HATs, HDACs, HMTs,
HDMs, DNMTs and TETs. While much has been learned about
the enzymatic mechanisms, largely based on crystal structures,
some aspects remain unclear as discussed above. Inhibitors
developed so far are mainly cofactor analogues and substrate
analogues, and some of them are approved for clinical use.
On the other hand, the modiﬁcations function in concert. There is
a clear evidence of cross-talk among epigenetic modiﬁcations64.
While individual enzymes are subject to detailed mechanistic studies
which can serve in the development of inhibitors, the inter-
connections between epigenetic modiﬁcation pathways may provide
new targets for the inhibition of these important biological actions.
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